Mumbai, Dec. 2 -- In a regulatory filing made during market hours today, the company stated that the U.S. District Court for the District of Columbia granted summary judgment in favour of SPARC in the matter of issuance of priority review voucher (PRV) associated with the approval of Sezaby.

The Court granted SPARC's motion for summary judgment and held that "FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved' as that term is used in the statute" and allowed 60 days to appeal against the motion.

Anil Raghavan, CEO, SPARC, said: "We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC's long held position on this matter."...